Hemophagocytic lymphohistiocytosis (HLH) is a serious hyperinflammatory condition in which excessive immune activation can cause persistent fever, cytopenias, organ dysfunction and other potentially life-threatening complications. In primary HLH, which is associated with inherited defects affecting immune-cell function, controlling the underlying inflammatory response is an important part of treatment while patients are evaluated for definitive therapy such as hematopoietic stem cell transplantation (HSCT).
Emapalumab-lzsg, marketed as Gamifant, is an interferon-gamma (IFNγ)-neutralizing monoclonal antibody used in the treatment of primary HLH when the disease is refractory, recurrent or progressive, or when conventional HLH therapy is not tolerated. The current U.S. prescribing information also includes an indication for HLH/macrophage activation syndrome associated with known or suspected Still’s disease.
For patients and families in India, however, the clinical value of a medicine is only one part of the equation. Questions about availability, regulatory access, import procedures, cold-chain handling and treatment cost can become equally important when a medicine is not routinely available through conventional domestic channels.
What is Emapalumab and What Does It Treat?
Emapalumab-lzsg is a fully human IgG1 monoclonal antibody that binds and neutralizes interferon gamma (IFNγ), a cytokine involved in the inflammatory pathway associated with HLH. By blocking IFNγ activity, Emapalumab helps reduce the downstream inflammatory signaling associated with macrophage activation. The medicine is administered intravenously and is intended to be used under specialist medical supervision. The U.S. FDA initially approved Emapalumab in 2018 for adult and pediatric patients with primary HLH whose disease is refractory, recurrent or progressive, or who are intolerant of conventional HLH therapy.
For primary HLH, the current prescribing information recommends a starting dose of 1 mg/kg administered intravenously over one hour twice weekly, generally every three to four days. Treatment is continued until HSCT is performed, unacceptable toxicity develops, or the patient no longer requires therapy for HLH. The dose can be increased when the response is considered inadequate. Dose modification is guided by clinical and laboratory findings, including parameters such as fever, platelet and neutrophil counts, ferritin, splenomegaly, D-dimer and fibrinogen. The maximum dose is 10 mg/kg.
This means that the quantity of Emapalumab required for an individual patient can vary considerably. Patient body weight, treatment duration and response to therapy all influence the total amount of medicine required.
Emapalumab Availability in India
Access to Emapalumab in India requires particular attention to regulatory status and procurement arrangements. The Indian regulatory framework provides a mechanism for importing small quantities of medicines for an individual’s personal medical use when the medicine is not otherwise available through the normal domestic route. The Central Drugs Standard Control Organization (CDSCO) describes this process under Rule 36 of the Drugs and Cosmetics Rules, 1945. The CDSCO’s personal-use procedure involves an application in Form 12A, accompanied by a prescription from a registered medical practitioner. Where the requirements are satisfied, permission is issued in Form 12B.
Therefore, patients who require Emapalumab and cannot obtain it through an established domestic supply route or from ordinary pharmacies, may need to explore the applicable personal-use import process with their treating hospital and the relevant regulatory authorities. A patient should not assume that a product advertised online is legally authorised for sale or that it has passed through an appropriate Indian import channel.
How the Personal-Use Import Process Works
The process begins with the treating physician establishing the medical need for the medicine and issuing the appropriate prescription. The prescription should identify the medicine and the quantity required for treatment. CDSCO’s procedure specifies that the prescription should come from a registered medical practitioner and include the practitioner’s registration number.
The applicant can then submit Form 12A for the required personal-use import. CDSCO states that the licensing authority may issue the corresponding Form 12B permit when the application establishes that the medicine is required for bona fide personal use and the quantity is reasonable and supported by the prescription. Form 12B permissions are issued on a priority basis, with its published procedure describing a timeframe of one or two days.
This is the regulatory processing description and should not be interpreted as a guarantee of the total time required to source, transport and clear a medicine internationally. Actual procurement can involve additional time for supplier confirmation, documentation, international transportation and customs clearance.
Cold-Chain Handling Is Essential
Gamifant is a temperature-sensitive biological medicine. The product information specifies refrigerated storage at 2°C to 8°C, protection from light, and that the product should not be frozen or shaken. This makes temperature-controlled transportation an important part of the supply process.
For an imported product, patients and hospitals should work through an appropriate pharmaceutical supply channel capable of maintaining the required storage conditions. Documentation relating to shipment and temperature control should be retained as part of the medicine’s supply record. Once received, the medicine should be handled and administered by appropriately qualified healthcare professionals.
How Much Does Emapalumab Cost?
The final amount required for an Indian patient can therefore differ substantially after taking into account the prescribed dose, number of vials required, exchange rates, procurement arrangements, transportation, customs-related expenses and other applicable charges. Several factors can affect the total financial requirement for Emapalumab treatment including body weight of patient, treatment duration, dose modification, etc. The Emapalumab cost can be substantial because treatment is weight-based and may continue for different lengths of time depending on the patient’s response and treatment plan.
Finally, an imported medicine can involve expenses beyond the medicine itself, including international logistics and temperature-controlled transportation. These costs cannot be reliably expressed as a single fixed amount because they depend on the individual procurement route.
Eligibility, funding availability and the treatment costs can sometimes be supported and should be confirmed directly with the relevant authority. Patients should not assume that financial assistance will automatically cover the entire cost of an imported biologic. Early discussion with the treating institution can be particularly important when a patient’s treatment plan involves both Emapalumab and HSCT.
Safety and Monitoring During Emapalumab Treatment
As Emapalumab neutralizes IFNγ, infection monitoring is an important component of treatment. The current FDA label warns about serious infections, including infections involving pathogens such as mycobacteria, herpes zoster virus and Histoplasma capsulatum. Patients should be evaluated for tuberculosis risk and tested for latent tuberculosis before treatment.
It is also recommended to consider prophylaxis against herpes zoster, Pneumocystis jirovecii and fungal infections, as clinically appropriate. During treatment, patients may require monitoring for infections including adenovirus, Epstein-Barr virus and cytomegalovirus. Infusion-related reactions can also occur. In the primary-HLH clinical safety population, commonly reported adverse reactions included infections, hypertension, infusion-related reactions and pyrexia.
These risks make specialist supervision essential. Emapalumab should not be obtained or administered without appropriate medical oversight.
Planning Access to Emapalumab in India
For families exploring Emapalumab access, early coordination between the treating specialist, hospital pharmacy or international procurement team and the appropriate regulatory authorities can help avoid unnecessary delays. A practical approach is to begin with:
- Confirming the indication with the treating specialist, determining whether Emapalumab is appropriate for the patient’s specific form and stage of HLH.
- Preparing the prescription and supporting medical documentation accurately describing the patient’s treatment requirement.
- Checking the regulatory route regarding Form 12A and Form 12B and where the medicine is being imported for personal use, the applicable CDSCO requirements should be fulfilled.
- Planning the supply chain as Emapalumab requires controlled storage conditions, transportation and handling arrangements before shipment.
- Estimating the complete treatment requirement: The treating team should calculate the expected dose and duration rather than relying on the price of a single vial.
- Exploring rare-disease support so that eligible patients can discuss available government and institutional support with a designated Centre of Excellence.
Conclusion
Emapalumab has provided an important targeted treatment option for patients with primary HLH whose disease is refractory, recurrent or progressive, or who cannot tolerate conventional HLH therapy. Its ability to neutralize IFNγ directly addresses an important component of the inflammatory pathway involved in HLH.
For patients in India, however, access requires more than identifying the medicine. Regulatory requirements, personal-use import procedures, temperature-controlled transportation and the potentially substantial cost of a weight-based treatment course all need to be considered. The safest approach is to begin with the treating specialist and hospital, establish the clinical requirement, and then follow the appropriate CDSCO import pathway where necessary. Patients and caregivers should also verify the source of the medicine and ensure that the product has been handled under the required storage conditions.
As regulatory requirements, product availability and pricing can change, the applicable CDSCO requirements and the current manufacturer information should be checked at the time of procurement rather than relying on an old price or access estimate.
